title: The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages.
abstract: Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the leading cause of death due to bacterial infections in mankind, and BCG, an attenuated strain of Mycobacterium bovis, is an approved vaccine. BCG sequesters in immature phagosomes of antigen presenting cells (APCs), which do not fuse with lysosomes, leading to decreased antigen processing and reduced Th1 responses. However, an Mtb derived ΔfbpA attenuated mutant underwent limited phagosome maturation, enhanced immunogenicity and was as effective as BCG in protecting mice against TB. To facilitate phagosome maturation of ΔfbpA, we disrupted an additional gene sapM, which encodes for an acid phosphatase. Compared to the wild type Mtb, the ΔfbpAΔsapM (double knock out; DKO) strain was attenuated for growth in mouse macrophages and PMA activated human THP1 macrophages. Attenuation correlated with increased oxidants in macrophages in response to DKO infection and enhanced labeling of lysosomal markers (CD63 and rab7) on DKO phagosomes. An in vitro Antigen 85B peptide presentation assay was used to determine antigen presentation to T cells by APCs infected with DKO or other mycobacterial strains. This revealed that DKO infected APCs showed the strongest ability to present Ag85B to T cells (>2500 pgs/mL in 4 hrs) as compared to APCs infected with wild type Mtb or ΔfbpA or ΔsapM strain (<1000 pgs/mL in 4 hrs), indicating that DKO strain has enhanced immunogenicity than other strains. The ability of DKO to undergo lysosomal fusion and vacuolar acidification correlated with antigen presentation since bafilomycin, that inhibits acidification in APCs, reduced antigen presentation. Finally, the DKO vaccine elicited a better Th1 response in mice after subcutaneous vaccination than either ΔfbpA or ΔsapM. Since ΔfbpA has been used in mice as a candidate vaccine and the DKO (ΔfbpAΔsapM) mutant is more immunogenic than ΔfbpA, we propose the DKO is a potential anti-tuberculosis vaccine.
authors.affiliation: Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, Edinburg, Texas, United States of America.
authors.forename: Sankaralingam
authors.initials: S
authors.lastname: Saikolappan
authors.forename: Jaymie
authors.initials: J
authors.lastname: Estrella
authors.forename: Smitha J
authors.initials: SJ
authors.lastname: Sasindran
authors.forename: Arshad
authors.initials: A
authors.lastname: Khan
authors.forename: Lisa Y
authors.initials: LY
authors.lastname: Armitige
authors.forename: Chinnaswamy
authors.initials: C
authors.lastname: Jagannath
authors.forename: Subramanian
authors.initials: S
authors.lastname: Dhandayuthapani
mesh_terms: D000217:Acyltransferases / Q000172:deficiency* / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics* / Q000276:immunology; D055786:Gene Knockout Techniques; D008247:Lysosomes / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D009154:Mutation; D009169:Mycobacterium tuberculosis / Q000235:genetics* / Q000276:immunology*; D010588:Phagosomes / Q000276:immunology; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D014613:Vaccines, Attenuated; D000217:Acyltransferases; C112580:antigen 85A, Mycobacterium tuberculosis